TCW Group Inc. Trims Stake in Pfizer Inc. $PFE

Key Points

• TCW Group reduced its Pfizer stake by 1.6% in the second quarter, selling 43,819 shares and retaining 2.67 million shares valued at approximately $64.3 million.
• Pfizer reported quarterly EPS of $0.77, beating estimates of $0.68, while revenue reached $15.03 billion and increased 2.6% year over year.
• Pfizer declared a quarterly dividend of $0.43, equal to an annualized $1.72 and a 6.4% yield. Analysts remain cautious, with a consensus “Hold” rating and a $28.28 price target.

TCW Group Inc. lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 1.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,669,765 shares of the biopharmaceutical company's stock after selling 43,819 shares during the quarter. TCW Group Inc.'s holdings in Pfizer were worth $64,288,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PFE. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the 4th quarter valued at approximately $26,000. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at $26,000. HFM Investment Advisors LLC lifted its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Evolution Wealth Management Inc. lifted its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $26.88 on Tuesday. The business has a fifty day moving average of $25.15 and a two-hundred day moving average of $26.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $153.21 billion, a P/E ratio of 35.37 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business's revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. HSBC lowered Pfizer from a "buy" rating to a "hold" rating and cut their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. UBS Group reiterated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. JPMorgan Chase & Co. dropped their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. Finally, Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source